Genetic testing can guide personalized AMD treatment

Article

During a presentation at SECO, Jeffry Gerson, OD, FAAO, said a simple genetic test gives optometrists the necessary information for developing a personalized care plan for patients with-or at risk for-age-related macular degeneration.

Atlanta, GA-During a presentation at SECO, Jeffry Gerson, OD, FAAO, said a simple genetic test gives optometrists the necessary information for developing a personalized care plan for patients with-or at risk for-age-related macular degeneration.

While other factors, such as age, weight, and whether a patient smokes, nothing can help predict the likelihood of a patient developing AMD over the next 2, 5, and 10 years like a genetic test. The test can also tell the optometrist which types of therapy would be most beneficial to the patient.

“It’s bad to be a smoker, when it comes to AMD.  It’s bad to have bad genetics. It’s really bad to have bad genes and be a smoker,” says Dr. Gerson. He said patients with bad genetics are at a 400xs greater risk for developing AMD than those with good genetics, and adding in smoking or other factors make that risk increases even more.

Dr. Gerson says he uses the Macula Risk test, which requires the patient to swab the inside of her cheek. The test is sent off to a lab and results are ready within 2-3 weeks.

If a patient has a diagnosis of drusen or AMD and has insurance, the test costs the patient about $25, says Dr. Gerson. For patients without insurance, the test costs $500-$700.

In addition to identifying patients who are most at risk for AMD, it can bring peace of mind to those who find they are not at risk for the disease.

“Our role is to be preventative and proactive. I ask myself, ‘If this were my mom, what would I do?’ And wouldn’t it be great to tell someone ‘You don’t have to worry’?” says Dr. Gerson.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Dr Luke Lindsell discusses retinal therapy and geographic atrophy at Controversies in Modern Eye Care 2025
Neda Shamie, MD, speaks on cataract and refractive surgery at CIME 2025.
Dr Selina McGee shares thoughts on pharmacological presbyopia correction at Controversies in Modern Eye Care 2025
Paul Hammond, OD, FAAO, presents a poster at ARVO 2025 on the creation of a conversion factor between 2 OCT devices to monitor glaucoma progression
What to know about legislative moves that have been made through May this year.
CIME 25: Dilsher Dhoot, MD, FASRS, is excited about emerging retinal therapies.
Robert Maloney, MD, MA, at the 2025 Controversies in Modern Eye Care meeting
Dr Jacob Lang at the 2025 Controversies in Modern Eye Care meeting
Steven Ferrucci, OD, FAAO, at Controversies in Modern Eyecare 2025
© 2025 MJH Life Sciences

All rights reserved.